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2009 to Dec 2010) and diagnosis of bipolar I mixed disorder (ICD-9-CM: 296.6x) from 
MarketScan® claims databases, yielded 230 ASE, 2726 aripiprazole, 984 olanzap-
ine, 3056 quetiapine, and 1623 risperidone patients. PS were derived using logistic 
regression models for ASE and each AA with baseline demographic and clinical 
characteristics as covariates. PS, inverse probability treatment weight (IPTW: 1/
PS ASE; 1/ (1-PS) AA), and standard mortality ratio weight (SMR: 1 ASE; PS/ (1-PS) 
AA) distributions were evaluated. ASE-AA un-weighted, IPTW, and SMR baseline 
characteristics were compared using standardized differences, chi-squares, and 
t-tests. Results: Un-weighted asenapine patients had pre-index greater bipolar 
I episodes rates, psychiatric drug use, dyslipidemia and obesity (all comparators). 
PS distributions for asenapine-olanzapine overlapped to some degree while PS of 
asenapine and the other comparators overlapped little to not at all. Comparing IPTW 
baseline characteristics, asenapine more resembled the AA cohorts. Demographic 
imbalance increased between asenapine and each AA. IPTW improved clinical char-
acteristic balance for asenapine versus olanzapine and risperidone, but only slightly 
improved imbalance versus aripiprazole and quetiapine. However some clinical 
characteristics not previously balanced in the un-weighted analyses for asenapine 
versus each AA were now imbalanced. Applying SMR, AA cohorts more resembled 
the asenapine cohort and all baseline demographic and clinical characteristics 
were finally balanced. ConClusions: SMR, a less common PS method, resulted 
in balanced baseline characteristics. SMR should be considered when IPTW leaves 
imbalance and the cohort of primary interest differs significantly from the broader 
underlying population to which it’s being compared.
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objeCtives: A challenge in multi-centre Time and Motion (T&M) studies is perform-
ing inferential statistics, in light of hierarchical data. Our objective was to investigate 
two approaches to analyze the data. Methods: Task-based approach analysed 
tasks independently, mean times were summed, and 95% confidence intervals 
(CIs) were computed based on Variance Sum Law I (assuming time is independ-
ent among all tasks). Case-based approach involved imputation for missing time; 
all tasks per observation were summed, and a single time variable was analysed. 
Both approaches were applied to three countries participating in a multi-country 
T&M study comparing intravenous [IV] and subcutaneous [SC] administration 
processes. Absolute and relative differences in country means (case-based minus 
task-based) and the difference in CI range were computed using a random intercept 
model, to account for centre clustering. Results: Mean times were similar for both 
approaches. For IV process, absolute (relative) differences in time were -0.03min 
(-0.1%) in France, -0.77min (-2.3%) in Italy, and -0.07min (-0.3%) in Russia. For SC 
process, results were 0.30min (2.1%) in France, 0.90min (4.5%) in Italy, and 0.01min 
(0.1%) in Russia. The differences in CI range between both approaches were notice-
able: 0.51min (5%) in France, 25.04min (57%) in Italy, and 10.06min (46%) in Russia for 
IV and 4.38min (40%) in France, 0.88min (5%) in Italy, and 8.19min (56%) in Russia for 
SC. ConClusions: The choice of task-based or case-based approach did not impact 
mean process time; however, since task-based approach assumed independence of 
task times, it resulted in much narrower CI range. On the other hand, case-based 
approach eliminates the underestimation of variations, thus may therefore be a 
more optimal choice to analyse time outcomes for complex processes. With only a 
single time variable being analysed, it also allows pooling of data across countries, 
therefore providing more power to generate reliable CIs.
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objeCtives: In health technology assessment (HTA) decisions about reimburse-
ment of new health technologies are largely based on effectiveness estimates 
obtained from pre-prepared meta-analysis of evidence from randomised con-
trolled trials. However, there is not always a consensus amongst the decision-
makers about the inclusion criteria of studies into the meta-analysis. Therefore an 
approach that allows stakeholders to manipulate the content of the meta-analysis, 
thus facilitating a critical sensitivity analysis in real time during the decision-
making process, would be valuable from the point of view of the transparency of 
the HTA submissions. A Graphical-User-Interface (GUI) was designed to facilitate 
such a transparent decision-making process. Methods: The GUI was designed 
using freely available software packages which included WinBUGS for develop-
ment of meta-analysis and meta-regression models and R which was used to 
design GUI, to link data with statistical models in WinBUGS and to extract the 
results. R was also used to develop graphical tools for presentation of results (for-
est and bubble plots) and for visual assessment of publication bias (funnel plots). 
Software was designed for an illustrative example in rheumatoid arthritis where 
effectiveness of TNF-alpha inhibitors was measured on different scales (DAS-
28, HAQ, ACR, and EULAR). Results: R-based Transparent Interactive Decision 
Interrogator (R-TIDI) was developed, which is a user-friendly tool with “point and 
click” options that allows users to choose an outcome measure and run random-
effects or fixed-effects meta-analysis and meta-regression models. Users are not 
required to have knowledge of statistical software or programming skills since 
the use of WinBUGS and R is entirely “behind the scenes”. R-TIDI enables users to 
interactively include/exclude studies from the meta-analysis allowing for conduct-
ing sensitivity analyses in real time. ConClusions: R-TIDI is a useful tool for 
non-statistical decision-makers. It allows users to run sensitivity meta-analyses 
widely used in manufacturers’ submissions to date. Of the most recent 60 NICE 
TAs, analyses employing MAIC methodology have been presented in two submis-
sions and a STC analysis in a single HTA, all in the oncology setting. In all cases 
the review group identified limitations with the statistical methodology presented, 
although their use as exploratory analyses supporting results from conventional 
meta-analyses was highlighted in one submission. In particular the use of non-
randomised data from single treatment arms was highlighted as a potential weak-
ness of STC. ConClusions: In spite of the increasing published evidence base 
reporting on MAIC in a range of indications, both MAIC and STC have not been 
widely used in manufacturer’s submission to NICE. Assessment bodies critiquing 
the technology submissions remain to be convinced of the appropriateness of these 
novel techniques for the robust assessment of relative efficacy.
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objeCtives: Meta-analysis is often conducted in OpenBUGS. This software, like 
all BUGS projects, is based on MCMC simulations by using Gibbs sampling. One 
of the main issues in the use of Markov chains in a continuous space is the chain 
convergence. If the chain does not converge, transient states will be accounted for 
in our posterior distributions. Since these states are not bound to the empirical data 
but only with the chain’s starting point, the estimated parameters of the posterior 
distribution will be biased. To help assessing the convergence of MCMC chain, sev-
eral methods exist. Methods: Based on the literature, we run several simulation 
scenarios in order to test built-in OpenBUGS graphical methods and to assess the 
power of the “thin” approach, a fixed-step jumping-data method, for convergence. 
Then, we focus on the existing diagnoses, their supplementary assumptions and 
their associated computation costs. To help perform these diagnoses directly on 
BUGS objects, we present the R-package coda. Results: The use of jumping-data 
method leads to loss of power and a poorer estimation of posterior distribution 
even in case of high autocorrelation. Consequently, the use of the thin method is 
not recommended to obtain a quicker convergence and better posterior distribution 
estimation. We have also seen that although autocorrelogram and trace can be use-
ful to assess convergence, they can lead to misinterpretation in case of extremely 
low number of studies and conclude to convergence. Alternatively, using the Geweke 
diagnosis seems, in terms of computation cost and assumptions, recommended for 
two main advantages: it gives a measure of trust of being in a stationary process and 
very low computation cost. ConClusions: We presented methods to assess con-
vergence of MCMC chains and argued on their pros and cons. The Geweke diagnose 
was found to provide best trade-off between computational cost and interpretability.
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objeCtives: Treatment crossover refers to the situation in randomised controlled 
trials (RCTs) where patients randomised to the control group switch onto the experi-
mental treatment. This leads to biased estimates of treatment effects if not appro-
priately controlled for. Several crossover adjustment methods are available, but 
previous research has shown that the optimal adjustment method depends upon 
the characteristics of the trial. This study applies crossover adjustment methods 
to an RCT comparing trametinib to chemotherapy in patients with BRAF V600E/K 
mutation-positive advanced or metastatic melanoma (NCT01245062), and investi-
gates which adjustment method best fits this case study. Methods: The crossover 
adjustment methods applied include the Rank Preserving Structural Failure Time 
Model (RPSFTM), Iterative Parameter Estimation (IPE) algorithm, Inverse Probability 
of Censoring Weights (IPCW) and a two-stage accelerated failure time model estima-
tion procedure. Suitability of each method is compared by assessing the plausibil-
ity of the underlying assumptions of the models in this case study and analysing 
output and performance indicators associated with each method. Results: In the 
primary efficacy population (patients without history of brain metastases) 67.4% of 
chemotherapy patients switched onto trametinib. The intention to treat (ITT) hazard 
ratio (HR) for overall survival (OS) was 0.72 (95% CI 0.52-1.01). Point-estimates of 
the adjusted HRs produced by the most plausible applications of the RPSFTM, IPE, 
IPCW and two-stage methods ranged between 0.43 and 0.49, consistently favouring 
trametinib. Results were sensitive to the technique used to apply each method. Key 
issues included recensoring, the active nature of the comparator, and the choice of 
covariates included in the analyses. ConClusions: Each of the crossover adjust-
ment methods result in a lower HR than the ITT analysis. However, results are 
uncertain and sensitive to key assumptions. It is important to carefully analyse trial 
characteristics and model output when identifying which applications of adjust-
ment methods are most plausible.
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objeCtives: Asenapine (ASE), an oral Atypical Antipsychotic (AA), was initially used 
for more severe bipolar I mixed disorder. Different propensity score (PS) methods 
were investigated to achieve balanced baseline characteristics between ASE and 
four oral AA cohorts for eventual outcomes analyses. Methods: Adults with ≥ 1 
asenapine, aripiprazole, olanzapine, quetiapine, or risperidone prescription fill (Aug 
